Star Therapeutics’ Post

View organization page for Star Therapeutics, graphic

2,132 followers

VGA039 offers exciting potential as a subcutaneous therapy for #VWD. The high bioavailability and favorable pharmacokinetic profile suggest it may have a product profile for infrequent, subcutaneous dosing for the treatment of VWD prophylaxis. 

Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD) - STAR Therapeutics

Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD) - STAR Therapeutics

https://star-therapeutics.com

To view or add a comment, sign in

Explore topics